interleukin-18 + interleukin-12

**Interleukin-18 + interleukin-12** is a combination cytokine immunotherapy consisting of recombinant IL-18 and recombinant IL-12 administered together to amplify cell-mediated antitumor immunity. The biological rationale is strong and well established: IL-12 primes NK cells and T cells and drives T helper 1 polarization, while IL-18 synergizes with IL-12 to markedly enhance interferon gamma production and cytotoxic immune activation. Historically, this combination has been investigated mainly as an experimental cancer immunotherapy in preclinical and early translational settings rather than as a standardized commercial drug product, and systemic coadministration has been associated with substantial inflammatory toxicity, which has limited broad clinical development. The term as written most often refers to a nonspecific therapeutic combination concept rather than a uniquely branded or standardized pharmaceutical product.

Other names

IL-18 + IL-12interleukin-12 + interleukin-18IL-12 + IL-18